“COVID vaccination increases the risk of catching COVID during the first two weeks.”

• Vaccines provide little or no protection in the first ~10-14 days after a dose, so people vaccinated during a surge can and do test positive in that window — making the period look 'risky' in raw counts. Randomized and real-world data consistently show efficacy curves only begin to diverge around day 12 after dose 1 (Polack et al., NEJM 2020; Dagan et al., NEJM 2021).
• Several observational datasets have produced apparent NEGATIVE vaccine effectiveness in the first days after a dose — i.e., slightly higher measured infection rates in the recently vaccinated than in the unvaccinated. This was reported in European long-term-care/healthcare-worker cohorts in early 2021 and is a recognized, repeatedly discussed artifact in the VE literature (Danish LTCF/HCW cohort analysis, 2021 preprint — specific citation omitted as I cannot verify the exact URL).
• Plausible non-immunological causal pathways exist for a small real increase in exposure: travel to and queuing at mass-vaccination sites, contact with clinic staff and other attendees, and behavioural relaxation ('risk compensation') immediately after getting the shot.
• Post-vaccination reactogenicity (fever, fatigue, sore throat) triggers extra testing, and transient post-mRNA changes in circulating lymphocyte counts have been described, which some researchers raised as a hypothesis for brief altered susceptibility.
• The UK SIREN healthcare-worker study and the Pfizer FDA briefing data both show the earliest post-dose interval contributing essentially zero measurable protection, which is the empirical basis people cite for this claim.
• Public-health messaging itself ('you are not protected for two weeks') is routinely misread as confirmation of increased risk, and the claim is therefore not invented out of nothing.

• No biological mechanism: authorized COVID-19 vaccines (mRNA, adenoviral-vector, protein subunit) contain no live or replication-competent SARS-CoV-2 and cannot cause or facilitate infection.
• Randomized placebo-controlled trials — the design that eliminates behavioural and exposure confounding — show no excess of confirmed COVID-19 in the vaccine arm in the early post-dose period. In the Pfizer trial, confirmed cases between dose 1 and dose 2 were 39 (vaccine) vs 82 (placebo); the Moderna trial showed the same direction. Cumulative-incidence curves overlap, they do not cross unfavourably in a statistically meaningful way.
• The apparent 'negative effectiveness' in observational studies is well explained by bias, not causation: people vaccinated during outbreaks are those with highest exposure (outbreak-driven vaccination in care homes), recently vaccinated people get tested more because vaccine side effects mimic COVID symptoms, pre-existing incubating infections are misattributed to the post-vaccination window, and misclassification of the vaccination-status denominator. Methodological papers using recently vaccinated individuals as a bias probe have demonstrated this directly.
• Large national real-world cohorts (Israel's Clalit cohort of ~1.2 million, UK SIREN) report VE in the 0-13 day window as approximately zero, not significantly negative — i.e., no protection, not added risk.
• Any residual early excess is attributable to exposure/behaviour around the vaccination event, which is a logistics problem, not a property of the vaccine; it disappears in trial settings where both arms attend the same clinics.
• The claim as written ('increases the risk of catching COVID') asserts causation by the vaccine, which no regulator (FDA, EMA, WHO, UKHSA, CDC) has found; all state only that protection takes about two weeks to develop.

76/100 — the lab’s own confidence in the score above, not a second reading of the claim.

New England Journal of Medicine (Polack et al., BNT162b2 Phase 3 trial)journal · 98 · New England Journal of Medicine (Baden et al., mRNA-1273 COVE trial)journal · 97 · New England Journal of Medicine (Dagan et al., Israel mass-vaccination cohort)journal · 96 · The Lancet (Hall et al., SIREN healthcare-worker cohort)journal · 95 · U.S. FDA — VRBPAC Briefing Document, Pfizer-BioNTech COVID-19 Vaccinegov · 95 · UK Health Security Agency — COVID-19 vaccine surveillance reportsgov · 90 · World Health Organization — COVID-19 vaccines Q&Agov · 88 · U.S. Centers for Disease Control and Preventiongov · 85

• Weak/indirect: protection is not immediate. CDC explains that it takes time after vaccination for the immune system to build protection, so people can be infected shortly before or shortly after vaccination and test positive during the first days afterward. This supports only a weaker claim: early post-vaccination cases happen; it does not show vaccination increases susceptibility.
• Weak/indirect: in the Pfizer randomized trial, cumulative COVID-19 case curves for vaccine and placebo recipients did not visibly separate until about 12 days after dose 1. That means little measurable protection in the earliest days, but the trial did not show an excess of infections caused by vaccination.
• Weak/indirect: crude real-world comparisons can sometimes make recently vaccinated groups look worse because vaccination may occur during surges, among higher-risk priority groups, or after an exposure that is already incubating. UKHSA specifically warned that simple case rates in vaccinated versus unvaccinated people are not valid measures of vaccine effectiveness because of confounding and population differences.

• The claim as written implies a causal increase in risk. Randomized trial evidence does not support that: Pfizer’s trial found overall efficacy after dose 1 and no signal that vaccinated participants were more likely than placebo participants to get COVID-19 in the first two weeks; early infections were largely consistent with exposure before immunity developed.
• Moderna’s randomized trial likewise found protection after vaccination and no evidence that the vaccine increased COVID-19 infection risk; the vaccine contains no live SARS-CoV-2 capable of causing COVID-19.
• Real-world studies show protection emerging around 12-14 days and strengthening afterward. Menni et al. found reduced infection risk after vaccination in a large UK app-based cohort; Dagan et al. found measurable effectiveness against documented infection from days 14-20 after the first Pfizer dose.
• CDC surveillance among U.S. health care personnel found mRNA vaccination was highly effective once immune response time had elapsed; the analysis defined partial immunization as at least 14 days after dose 1, consistent with the point that the first two weeks are a ramp-up period, not a period of vaccine-caused increased susceptibility.
• Apparent infections shortly after vaccination are explainable by incubation period, exposure before/around the appointment, testing behavior, and confounding. They are not evidence that COVID vaccination biologically increases the risk of catching COVID.

86/100 — the lab’s own confidence in the score above, not a second reading of the claim.

CDCgov · 92 · New England Journal of Medicinejournal · 96 · New England Journal of Medicinejournal · 96 · New England Journal of Medicinejournal · 95 · CDC MMWRgov · 93 · The Lancet Infectious Diseasesjournal · 94 · UK Health Security Agencygov · 90 · FactCheck.orgfactcheck · 88

• Raw observational data from early vaccine rollouts in countries like the UK and Israel showed a statistical spike in positive COVID-19 tests during the first 1-14 days following a first vaccine dose.
• Some vaccine recipients experienced expected immune responses (like fever or fatigue) that mimicked COVID-19 symptoms, prompting them to get tested. This led to the discovery of asymptomatic or incubating infections that were acquired before or during the vaccination process.

• Biologically, authorized COVID-19 vaccines do not contain live SARS-CoV-2 virus and cannot cause COVID-19. They also do not induce temporary immunosuppression or physically increase susceptibility to the virus.
• Public health experts and epidemiologists widely attribute the temporary statistical spike in post-vaccination infections to behavioral factors. This includes individuals prematurely dropping pandemic precautions (assuming immediate protection) or being exposed to the virus at busy mass vaccination centers.
• The immune system requires approximately 10 to 14 days to build significant protective immunity after receiving a dose. Infections occurring during this window represent a lack of instantaneous protection against prior or concurrent exposures, not an increased biological risk caused by the vaccine.
• Fact-checkers and immunologists have repeatedly debunked the claim that the vaccine suppresses the immune system during the first two weeks, classifying the correlation between recent vaccination and infection as a behavioral and statistical artifact rather than a causal, biological link.

95/100 — the lab’s own confidence in the score above, not a second reading of the claim.

The BMJjournal · 95

• Protection does not develop immediately: the CDC says immunity can take weeks to develop, so infection acquired shortly before or after vaccination may still occur; this establishes vulnerability during the early period, but does not show that vaccination causes extra infections [1].
• A real-world study of nearly 4,000 U.S. healthcare workers and first responders found an 80% reduction in infection risk beginning two weeks or more after the first mRNA dose, implying little or no demonstrated protection before that point rather than a proven increase in risk [5].
• A peer-reviewed study reported no decrease in PCR-confirmed infection during the first two weeks after a first Pfizer dose compared with being unvaccinated [8].

• The CDC explains that vaccines require time to generate immune responses and that infection can occur in the weeks immediately following vaccination; this is a lack of immediate protection, not evidence that vaccination increases susceptibility [1][2].
• The same real-world study found substantially reduced infection risk after vaccination—about 80% after the first dose and 90% two weeks after the second dose [5].
• The peer-reviewed study found no reduction, rather than an increase, in infection risk during the first two weeks after the first dose [8].
• CDC guidance states that COVID vaccines reduce the risk of COVID-19 illness and urgent-care or emergency-department visits, supporting an overall protective effect, although this does not specifically quantify the first 14 days [3].

91/100 — the lab’s own confidence in the score above, not a second reading of the claim.

Centers for Disease Control and Preventiongov · 96 · Centers for Disease Control and Preventiongov · 96 · Centers for Disease Control and Preventiongov · 96 · Reutersnews · 93 · University of Glasgow / Vaccinejournal · 88 · Centers for Disease Control and Preventiongov · 96

• Some early 2021 observational cohorts (Israel, UK health-care workers, and similar settings) recorded a higher crude incidence of positive SARS-CoV-2 tests in the 0–14 days after dose 1 than in contemporaneous unvaccinated comparators.
• Immediate post-vaccination relaxation of distancing or masking, plus people attending vaccination appointments while already incubating infection, can produce an apparent excess of detections in that window.

• Phase-3 RCTs of BNT162b2 and mRNA-1273 showed no rise in COVID-19 cases in the vaccine arms during the first two weeks; cumulative-incidence curves remained similar or began to separate in favor of vaccination around day 10–14.
• The authorized COVID-19 vaccines contain no live SARS-CoV-2 and have no established mechanism that would biologically increase susceptibility in the short term.
• Standard VE analyses treat days 0–13 as a pre-immunity period and attribute any observational excess to confounding (incubating cases at vaccination, differential testing prompted by reactogenicity, or behavior change), not to the vaccine raising risk.
• Protection against infection is documented to begin accruing after approximately 10–14 days, consistent with the kinetics of neutralizing-antibody and T-cell responses.

78/100 — the lab’s own confidence in the score above, not a second reading of the claim.

New England Journal of Medicinejournal · 96 · New England Journal of Medicinejournal · 96 · CDCgov · 90 · The Lancetjournal · 95